Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 15/20 | 1.00 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602182 | 1.00 | CETP (1.00) | CETPMMEMDM4TP53 | |
| SCHEMBL29352140 | 1.00 | CETP (1.00) | CETPMMEMDM4TP53 | |
| Hydrogen Sulfide SCHEMBL28096222 | 0.99 | CETP (0.97) | CETPMMEMDM4TP53 | |
| SCHEMBL9943229 | 0.93 | CETP (0.87) | CETPMMEMDM4TP53 | |
| SCHEMBL14408429 | 0.87 | CETP (0.77) | CETPTP53 | |
| SCHEMBL21252687 | 0.87 | CETP (0.76) | CETPMME | |
| SCHEMBL2490285 | 0.87 | CETP (0.77) | CETPMME | |
| SCHEMBL528151 | 0.87 | CETP (0.77) | CETPMMEMDM4TP53 | |
| SCHEMBL529244 | 0.87 | CETP (1.00) | CETPMMEMDM4TP53 | |
| SCHEMBL1534085 | 0.86 | CETP (0.76) | CETPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | claimed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | claimed |
| US-20190224147-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-07-25 | — | — | US | claimed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | claimed |
| WO-2019043018-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2019-03-07 | — | — | WO | claimed |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2018-02-22 | — | — | US | claimed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | claimed |
| EP-3082784-A1 | CETP MODULATOR FOR USE IN THE TREATMENT OF EYE DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2016-10-26 | — | — | EP | claimed |
| US-20160287537-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | claimed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | claimed |
| WO-2005030185-A2 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | WO | claimed |
| US-20050020668-A1 | Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | claimed |
| WO-2004098583-A1 | COMBINATION COMPRISING S-[2-([[1-(2-ETHYLBUTYL)CYCLOHEXYL]CARBONYL]AMINO)PHENYL]2-METHYLPROPANETHIOATE AND AN HMG COA REDUCTASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | WO | claimed |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | JAPAN TOBACCO INC. (JP) | 2004-11-11 | — | — | US | claimed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | claimed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | claimed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885MME 671/4885MDM4 4594/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885MME 466/4885MDM4 4274/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | CETP 311/4885MME 317/4885MDM4 4145/4885 |
| US-20160287537-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | CETP, MTTP, APOB | CETP 1/4885MME 568/4885MDM4 4597/4885 |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | CETP, LCAT, MTTP | CETP 1/4885MME 881/4885MDM4 1483/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CETP 10/4885MME 1171/4885MDM4 3317/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CETP 10/4885MME 1171/4885MDM4 3317/4885 |
| US-20190224147-A1 | CETP MODULATOR FOR USE IN THE TREATEMENT OF EYE DISEASE | CETP, MTTP, APOB | CETP 1/4885MME 441/4885MDM4 4516/4885 |
| US-20050020668-A1 | Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor | HMGCR, COASY, PCSK9 | CETP 8/4885MME 2094/4885MDM4 4120/4885 |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | CETP, MTTP, PCTP | CETP 1/4885MME 1823/4885MDM4 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.